BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $437,783,179 | +2.4% | 11,599,978 | +23.6% | 0.12% | +5.4% |
| Q2 2023 | $427,695,882 | +114.7% | 9,387,530 | +91.2% | 0.11% | +100.0% |
| Q1 2023 | $199,169,434 | +1.3% | 4,910,489 | +27.3% | 0.06% | -3.4% |
| Q4 2022 | $196,540,422 | +73.4% | 3,856,002 | +83.2% | 0.06% | +61.1% |
| Q3 2022 | $113,349,000 | -40.9% | 2,104,522 | -29.5% | 0.04% | -37.9% |
| Q2 2022 | $191,758,000 | -12.3% | 2,985,465 | +5.9% | 0.06% | +3.6% |
| Q1 2022 | $218,614,000 | -8.4% | 2,819,382 | +1.4% | 0.06% | -3.4% |
| Q4 2021 | $238,664,000 | +8.6% | 2,780,343 | +1.7% | 0.06% | +3.6% |
| Q3 2021 | $219,826,000 | -20.8% | 2,733,146 | -20.7% | 0.06% | -17.6% |
| Q2 2021 | $277,459,000 | +19.5% | 3,446,702 | +25.2% | 0.07% | +9.7% |
| Q1 2021 | $232,163,000 | +33.9% | 2,752,720 | +27.4% | 0.06% | +24.0% |
| Q4 2020 | $173,393,000 | -10.7% | 2,160,915 | -10.5% | 0.05% | -24.2% |
| Q3 2020 | $194,257,000 | -1.0% | 2,415,514 | +6.0% | 0.07% | -5.7% |
| Q2 2020 | $196,193,000 | +9.8% | 2,278,692 | +3.5% | 0.07% | -6.7% |
| Q1 2020 | $178,713,000 | -1.4% | 2,201,155 | +1.6% | 0.08% | +33.9% |
| Q4 2019 | $181,189,000 | -6.3% | 2,166,810 | -1.9% | 0.06% | +9.8% |
| Q3 2019 | $193,286,000 | +36.4% | 2,209,751 | +27.7% | 0.05% | +41.7% |
| Q2 2019 | $141,740,000 | -3.6% | 1,730,638 | -4.3% | 0.04% | -28.0% |
| Q1 2019 | $147,031,000 | +52.1% | 1,808,262 | +23.1% | 0.05% | +35.1% |
| Q4 2018 | $96,692,000 | -57.5% | 1,469,057 | -50.3% | 0.04% | -48.6% |
| Q3 2018 | $227,773,000 | -45.2% | 2,954,640 | -47.6% | 0.07% | -47.8% |
| Q2 2018 | $415,981,000 | -3.4% | 5,633,556 | -14.9% | 0.14% | -14.3% |
| Q1 2018 | $430,415,000 | -5.2% | 6,617,707 | -5.8% | 0.16% | -1.8% |
| Q4 2017 | $453,944,000 | +15.8% | 7,022,668 | +12.4% | 0.16% | +13.1% |
| Q3 2017 | $392,015,000 | -13.8% | 6,247,279 | -16.9% | 0.14% | +2.1% |
| Q2 2017 | $455,016,000 | +6.1% | 7,515,987 | -9.1% | 0.14% | +0.7% |
| Q1 2017 | $428,979,000 | +7.2% | 8,271,892 | -8.4% | 0.14% | +4.4% |
| Q4 2016 | $400,227,000 | -14.2% | 9,026,292 | -7.9% | 0.14% | -15.6% |
| Q3 2016 | $466,468,000 | +16.5% | 9,799,811 | +10.7% | 0.16% | +8.8% |
| Q2 2016 | $400,412,000 | -1.6% | 8,854,759 | -10.6% | 0.15% | -10.9% |
| Q1 2016 | $406,888,000 | +18.2% | 9,904,766 | +9.8% | 0.16% | +20.4% |
| Q4 2015 | $344,246,000 | +5.7% | 9,023,507 | -9.0% | 0.14% | -0.7% |
| Q3 2015 | $325,751,000 | -37.6% | 9,916,319 | +32.8% | 0.14% | -32.7% |
| Q2 2015 | $522,343,000 | +27.7% | 7,469,483 | +25.1% | 0.20% | +29.7% |
| Q1 2015 | $409,152,000 | +66.3% | 5,973,015 | +77.9% | 0.16% | +66.3% |
| Q4 2014 | $246,016,000 | +15.7% | 3,356,738 | +13.3% | 0.10% | +11.8% |
| Q3 2014 | $212,605,000 | +34.9% | 2,962,321 | +35.9% | 0.08% | +37.1% |
| Q2 2014 | $157,605,000 | -38.7% | 2,179,878 | -37.6% | 0.06% | -40.4% |
| Q1 2014 | $256,961,000 | +57.8% | 3,492,245 | +49.2% | 0.10% | +60.0% |
| Q4 2013 | $162,847,000 | +8.3% | 2,341,426 | +2.3% | 0.06% | 0.0% |
| Q3 2013 | $150,347,000 | -32.6% | 2,288,742 | -28.9% | 0.06% | -37.5% |
| Q2 2013 | $222,983,000 | – | 3,219,027 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |